Tecovirimat Use under Expanded Access to Treat Mpox in the United States, 2022-2023.

ABSTRACT:

Background

During the ongoing outbreak of clade II monkeypox virus (MPXV), many U.S. patients were prescribed tecovirimat, an antiviral drug that was made available under an expanded access Investigational New Drug (EA-IND) program. We evaluated EA-IND data to summarize characteristics of treated patients, outcomes, and serious adverse events (SAEs).

Methods

We evaluated data from patients prescribed tecovirimat from May 29, 2022, through July 10, 2023. Baseline patient characteristics, clinical courses, and outcomes were evaluated via intake forms, outcome forms, and patient diaries. Data were summarized in aggregate by human immunodeficiency virus (HIV) status and by comorbidities of special interest. Reported SAEs were also compiled.

Results

Tecovirim

SUBMITTER: Yu PA 

PROVIDER: S-EPMC11421955 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature